737 related articles for article (PubMed ID: 28412770)
1. Anemia in chronic kidney disease.
Atkinson MA; Warady BA
Pediatr Nephrol; 2018 Feb; 33(2):227-238. PubMed ID: 28412770
[TBL] [Abstract][Full Text] [Related]
2. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
4. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
5. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
Del Vecchio L; Locatelli F
Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
[TBL] [Abstract][Full Text] [Related]
6. Iron Metabolism in Chronic Kidney Disease Patients.
Honda H; Hosaka N; Ganz T; Shibata T
Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
[TBL] [Abstract][Full Text] [Related]
7. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
8. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
10. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
11. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
12. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
[TBL] [Abstract][Full Text] [Related]
13. Investigational therapies for renal disease-induced anemia.
Schmid H; Jelkmann W
Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
[TBL] [Abstract][Full Text] [Related]
14. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
Wyatt CM; Drüeke TB
Kidney Int; 2016 Nov; 90(5):923-925. PubMed ID: 27742192
[TBL] [Abstract][Full Text] [Related]
15. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
Wish JB
Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360
[No Abstract] [Full Text] [Related]
16. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
17. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
18. Anemia management in dialysis patients: a PIVOT and a new path?
Nair S; Trivedi M
Curr Opin Nephrol Hypertens; 2020 May; 29(3):351-355. PubMed ID: 32235274
[TBL] [Abstract][Full Text] [Related]
19. Anaemia in CKD-treatment standard.
Macdougall IC
Nephrol Dial Transplant; 2024 Apr; 39(5):770-777. PubMed ID: 38012124
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]